Presents the case of a 55-year-old white man diagnosed with epidermolysis bullosa acquisita, a rare acquired autoimmune disease. Significant reduction of the incidence of acute rejection episodes after prophylaxis with basiliximab, an interleukin-2 receptor antibody; Absence of clinically relevant safety or tolerability concerns.